Apr-30-24 07:10AM
|
|
07:03AM
|
|
07:02AM
|
|
07:00AM
|
|
03:41AM
|
|
02:36PM |
Loading… |
Apr-29-24 02:36PM
|
|
02:17PM
|
|
01:41PM
|
|
01:02PM
|
(Pharmaceutical Technology) |
12:17PM
|
|
12:16PM
|
|
11:19AM
|
|
10:46AM
|
|
10:33AM
|
|
09:57AM
|
|
09:02AM |
Loading… |
09:02AM
|
|
08:54AM
|
|
07:29AM
|
|
07:29AM
|
|
07:29AM
|
|
07:18AM
|
|
07:06AM
|
|
07:00AM
|
|
Apr-24-24 10:01AM
|
|
Apr-21-24 10:39AM
|
|
Apr-09-24 07:00AM
|
|
Mar-07-24 11:31AM
|
|
Mar-04-24 08:28PM
|
|
Feb-28-24 09:55AM
|
|
Feb-27-24 07:00AM
|
|
09:55AM |
Loading… |
Feb-12-24 09:55AM
|
|
Feb-07-24 09:20AM
|
|
08:28AM
|
|
12:33AM
|
(Thomson Reuters StreetEvents) |
Feb-06-24 07:00AM
|
|
Feb-01-24 04:50PM
|
|
07:00AM
|
|
Jan-30-24 10:01AM
|
|
Jan-18-24 11:13AM
|
|
Jan-08-24 07:00AM
|
|
Jan-05-24 07:00AM
|
|
Jan-02-24 07:00AM
|
|
Dec-15-23 07:06AM
|
|
Dec-02-23 07:08AM
|
|
Nov-29-23 11:30AM
|
|
07:00AM
|
|
Nov-07-23 07:00AM
|
|
Nov-01-23 03:03AM
|
|
Oct-31-23 07:25AM
|
|
04:51AM
|
(Thomson Reuters StreetEvents) |
01:16AM
|
|
Oct-30-23 08:15AM
|
|
07:01AM
|
|
07:00AM
|
|
Oct-16-23 12:39PM
|
|
Oct-05-23 11:38AM
|
|
Sep-29-23 09:00AM
|
|
Sep-22-23 12:02PM
|
|
11:46AM
|
|
Sep-15-23 05:00PM
|
|
Sep-08-23 11:30AM
|
|
Aug-21-23 07:43PM
|
|
Aug-19-23 07:40AM
|
|
Aug-18-23 04:05PM
|
|
Aug-11-23 03:30PM
|
|
Aug-10-23 08:13AM
|
|
Aug-09-23 08:50AM
|
|
07:00AM
|
|
Aug-03-23 04:15PM
|
|
Aug-02-23 07:00AM
|
|
Jun-09-23 09:02AM
|
|
Jun-02-23 11:31AM
|
|
May-25-23 05:00PM
|
|
May-23-23 07:00AM
|
|
May-08-23 01:31PM
|
|
07:00AM
|
|
May-04-23 05:38AM
|
|
May-03-23 08:15AM
|
|
07:00AM
|
|
Apr-27-23 10:03AM
|
|
Apr-26-23 10:02AM
|
|
07:00AM
|
|
Apr-19-23 07:00AM
|
|
Apr-18-23 06:53AM
|
|
Mar-23-23 11:30AM
|
|
Mar-16-23 05:25PM
|
|
Mar-15-23 11:52AM
|
|
06:28AM
|
|
Mar-14-23 05:53PM
|
|
05:32PM
|
|
04:26AM
|
|
Mar-09-23 11:30AM
|
|
Mar-01-23 07:00AM
|
|
Feb-27-23 07:00AM
|
|
Feb-08-23 02:13PM
|
|
08:43AM
|
|
05:40AM
|
|
Feb-07-23 08:35AM
|
|
07:00AM
|
|
Feb-02-23 07:00AM
|
|
|
|
|
Deciphera Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors, advanced systemic mastocytosis, gliomas, and other solid tumors. The company was founded by Peter A. Petillo and Daniel L. Flynn in 2003 and is headquartered in Waltham, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kelly Thomas Patrick | Chief Financial Officer | Feb 16 '24 | Sale | 15.62 | 3,010 | 47,009 | 80,350 | Feb 20 04:05 PM | Sherman Matthew L | EVP & Chief Medical Officer | Feb 16 '24 | Sale | 15.62 | 2,615 | 40,840 | 108,739 | Feb 20 04:06 PM | Pitman Jama | SVP, Chief Development Officer | Feb 16 '24 | Sale | 15.62 | 2,267 | 35,405 | 68,031 | Feb 20 04:05 PM | Martin Daniel C. | Chief Commercial Officer | Feb 16 '24 | Sale | 15.62 | 2,267 | 35,405 | 55,118 | Feb 20 04:05 PM | Kelly Thomas Patrick | Chief Financial Officer | Jan 16 '24 | Sale | 14.47 | 2,435 | 35,234 | 66,085 | Jan 18 04:15 PM | Sherman Matthew L | EVP & Chief Medical Officer | Jan 16 '24 | Sale | 14.47 | 2,435 | 35,234 | 94,079 | Jan 18 04:15 PM | Pitman Jama | SVP, Chief Development Officer | Jan 16 '24 | Sale | 14.47 | 1,624 | 23,499 | 50,573 | Jan 18 04:15 PM | Martin Daniel C. | Chief Commercial Officer | Jan 16 '24 | Sale | 14.47 | 1,624 | 23,499 | 47,660 | Jan 18 04:15 PM | Hoerter Steven L. | President and CEO | Dec 13 '23 | Sale | 15.37 | 30,664 | 471,217 | 72,763 | Dec 14 04:05 PM | Kelly Thomas Patrick | Chief Financial Officer | Dec 13 '23 | Sale | 15.37 | 2,792 | 42,905 | 68,520 | Dec 14 04:05 PM | Sherman Matthew L | EVP & Chief Medical Officer | Dec 13 '23 | Sale | 15.37 | 2,792 | 42,905 | 96,514 | Dec 14 04:05 PM | Martin Daniel C. | Chief Commercial Officer | Dec 13 '23 | Sale | 15.37 | 1,727 | 26,539 | 49,284 | Dec 14 04:05 PM | Pitman Jama | See Remarks | Dec 13 '23 | Sale | 15.37 | 1,662 | 25,540 | 52,197 | Dec 14 04:05 PM | Martin Daniel C. | Chief Commercial Officer | Nov 30 '23 | Sale | 12.57 | 17,801 | 223,755 | 45,435 | Dec 01 04:05 PM | Hoerter Steven L. | President and CEO | Oct 30 '23 | Sale | 12.02 | 21,573 | 259,256 | 40,927 | Oct 31 04:09 PM | Sherman Matthew L | EVP & Chief Medical Officer | Oct 30 '23 | Sale | 12.02 | 2,360 | 28,362 | 90,628 | Oct 31 04:11 PM | Kelly Thomas Patrick | Chief Financial Officer | Oct 30 '23 | Sale | 12.02 | 2,316 | 27,833 | 63,068 | Oct 31 04:09 PM | Martin Daniel C. | Chief Commercial Officer | Oct 30 '23 | Sale | 12.02 | 1,407 | 16,909 | 62,884 | Oct 31 04:10 PM | Pitman Jama | See Remarks | Oct 30 '23 | Sale | 12.02 | 1,407 | 16,909 | 48,283 | Oct 31 04:10 PM | Sherman Matthew L | EVP & Chief Medical Officer | Oct 02 '23 | Sale | 12.68 | 2,942 | 37,305 | 84,744 | Oct 04 04:05 PM | Flynn Daniel Lee | Chief Scientific Officer | Jun 16 '23 | Sale | 14.40 | 1,655 | 23,835 | 57,158 | Jun 21 04:05 PM | Kelly Thomas Patrick | Chief Financial Officer | Jun 16 '23 | Sale | 14.40 | 1,655 | 23,835 | 57,140 | Jun 21 04:05 PM | Sherman Matthew L | EVP & Chief Medical Officer | Jun 16 '23 | Sale | 14.40 | 1,655 | 23,835 | 87,686 | Jun 21 04:05 PM | Pitman Jama | See Remarks | Jun 16 '23 | Sale | 14.40 | 1,238 | 17,829 | 43,812 | Jun 21 04:05 PM | Martin Daniel C. | Chief Commercial Officer | Jun 16 '23 | Sale | 14.40 | 1,238 | 17,829 | 58,413 | Jun 21 04:05 PM | Friedman Franklin Stuart | Director | Jun 08 '23 | Buy | 13.88 | 10,000 | 138,828 | 10,000 | Jun 12 04:05 PM | Walsh Dennis Leo | Director | May 10 '23 | Buy | 13.86 | 11,000 | 152,416 | 11,000 | May 12 04:05 PM |
|